Objectives: Cutaneous anthrax (CA) is the most common clinical presentation in human anthrax, but the duration of antibiotic therapy in naturally occurring CA is controversial. The aim of this study was to compare the clinical outcomes of patients receiving antibiotic treatment for either 3-5 days (group 1) or 7-10 days (group 2) in uncomplicated CA. Methods: A total of 66 patients were enrolled; 29 (44%) in group 1 and 37 (56%) in group 2. Infections were classified as mild (n = 22, 33%) or severe (n = 44, 67%) CA. Results: There were no significant differences between the groups in symptom resolution time, fever clearance time, healing of lesions, development and healing of eschars, requirement for surgical intervention or the development of complications. Both edema resolution time and duration of hospital stay were longer in group 2. There were no therapeutic failures, relapses or deaths in either group. Steroid therapy was used in 32% of patients with severe CA, but a beneficial effect on resolution of edema was not demonstrated. Conclusions: These results suggest that short-course antibiotic therapy is as effective as standard-duration therapy in uncomplicated CA and that steroid therapy may not be effective.

Keywords:
Anthrax, Antimicrobial therapy, Bacillus anthracis, Bacterial infection, Cutaneous anthrax, Gram-positive bacteria
1.
Brook I: The prophylaxis and treatment of anthrax. Int J Antimicrob Agents 2002;20:320-325.
2.
Bouzianas DG: Current and future medical approaches to combat the anthrax threat. J Med Chem 2010;53:4305-4331.
3.
Ozcan H, Kayabas U, Bayindir Y, Bayraktar MR, Ay S: Evaluation of 23 cutaneous anthrax patients in eastern Anatolia, Turkey: diagnosis and risk factors. Int J Dermatol 2008;47:1033-1037.
4.
Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Schoch-Spana M, Tonat K: Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002;287:2236-2252.
5.
Kaya A, Tasyaran MA, Erol S, Ozkurt Z, Ozkan B: Anthrax in adults and children: a review of 132 cases in Turkey. Eur J Clin Microbiol Infect Dis 2002;21:258-261.
6.
Doganay M: Anthrax; in Cohen J, Opal SM, Powderly WG (eds): Infectious Diseases, ed 3. Amsterdam, Elsevier, 2010, pp 1257-1261.
7.
Doganay M, Metan G: Human anthrax in Turkey from 1990 to 2007. Vector Borne Zoonotic Dis 2009;9:131-140.
8.
Ronaghy HA, Azadeh B, Kohout E, Dutz W: Penicillin therapy of human cutaneous anthrax. Curr Ther Res Clin Exp 1972;14:721-725.
9.
Doganay M, Metan G, Alp E: A review of cutaneous anthrax and its outcome. J Infect Public Health 2010;3:98-105.
10.
Gold H: Anthrax: A report of one hundred seventeen cases. Arch Intern Med 1955;96:387-396.
11.
Kobuch WE, Davis J, Fleischer K, Isaacson M, Turnbull PCB: A clinical and epidemiological study of 621 patients with anthrax in western Zimbabwe. Proceedings of the international workshop on anthrax. Salisbury Med Bull 1990;68(suppl):34-38.
12.
World Health Organization, Food and Agriculture Organization of the United Nations and World Organisation for Animal Health. Anthrax in Humans and Animals, ed 4. Available from: http://www.who.int/csr/resources/publications/anthrax_webs.pdf
13.
Ellingson HV, Bookwalter HL, Howe C: Cutaneous anthrax; report of twenty-five cases. JAMA 1946;131:1105-1108.
14.
Akbayram S, Doğan M, Akgün C, Peker E, Bektaş MS, Kaya A, Caksen H, Oner AF: Clinical findings in children with cutaneous anthrax in eastern Turkey. Pediatr Dermatol 2010;27:600-606.
15.
Karahocagil MK, Akdeniz N, Akdeniz H, Calka O, Karsen H, Bilici A, Bilgili SG, Evirgen O: Cutaneous anthrax in Eastern Turkey: a review of 85 cases. Clin Exp Dermatol 2008;33:406-411.
16.
Maguiña C, Flores Del Pozo J, Terashima A, Gotuzzo E, Guerra H, Vidal JE, Legua P, Solari L: Cutaneous anthrax in Lima, Peru: retrospective analysis of 71 cases, including four with a meningoencephalic complication. Rev Inst Med Trop Sao Paulo 2005;47:25-30.
17.
Dixon TC, Meselson M, Guillemin J, Hanna PC: Anthrax. N Engl J Med 1999;341:815-826.
18.
Seifert H, Dowzicky MJ. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007). Chemotherapy 2009;55:241-252.
19.
Esel D, Doganay M, Sumerkan B: Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey. Int J Antimicrob Agents 2003;22:70-72.
20.
Swartz MN: Recognition and management of anthrax - an update. N Engl J Med 2001;345:1621-1626.
21.
Cavallo JD, Ramisse F, Girardet M, Vaissaire J, Mock M, Hernandez E: Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob Agents Chemother 2002;46:2307-2309.
22.
Turnbull PC, Sirianni NM, LeBron CI, Samaan MN, Sutton FN, Reyes AE, Peruski LF Jr: MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol 2004;42:3626-3634.
23.
Lightfoot NF, Scott RJD, Turnbull PC: An-timicrobial susceptibility of Bacillus an-thracis. Salisbury Med Bull 1990;68(spec suppl):95-98.
24.
Mohammed MJ, Marston CK, Popovic T, Weyant RS, Tenover FC: Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods. J Clin Microbiol 2002;40:1902-1907.
25.
Coker PR, Smith KL, Hugh-Jones ME: Antimicrobial susceptibilities of diverse Bacillus anthracis isolates. Antimicrob Agents Chemother 2002;46:3843-3845.
26.
Maho A, Rossano A, Hächler H, Holzer A, Schelling E, Zinsstag J, Hassane MH, Toguebaye BS, Akakpo AJ, Van Ert M, Keim P, Kenefic L, Frey J, Perreten V: Antibiotic susceptibility and molecular diversity of Bacillus anthracis strains in Chad: detection of a new phylogenetic subgroup. J Clin Microbiol 2006;44:3422-3425.
27.
Luna VA, King DS, Gulledge J, Cannons AC, Amuso PT, Cattani J: Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre automated microbroth dilution and Etest agar gradient diffusion methods. J Antimicrob Chemother 2007;60:555-567.
28.
Metan G, Doganay M: The antimicrobial susceptibility of Bacillus anthracis isolated from human cases: a review of the Turkish literature. Turkiye Klinikleri J Med Sci 2009;29:229-235.
29.
Oncul O, Ozsoy MF, Gul HC, Koçak N, Cavuslu S, Pahsa A: Cutaneous anthrax in Turkey: a review of 32 cases. Scand J Infect Dis 2002;34:413-416.
30.
Doganay M, Aydin N: Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis 1991;23:333-335.
31.
Bakici MZ, Elaldi N, Bakir M, Dökmetaş I, Erandaç M, Turan M: Antimicrobial susceptibility of Bacillus anthracis in an endemic area. Scand J Infect Dis 2002;34:564-566.
32.
Demirdag K, Ozden M, Saral Y, Kalkan A, Kilic SS, Ozdarendeli A: Cutaneous anthrax in adults: a review of 25 cases in the eastern Anatolian region of Turkey. Infection 2003;31:327-330.
33.
Martin GJ, Friedlander AM: Bacillus anthracis (Anthrax); in Mandell GL, Bennett JE, Dolin R (eds): Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, ed 7. Philadelphia, Churchill Livingstone, 2010, pp 2715-2725.
34.
Stern EJ, Uhde KB, Shadomy SV, Messonnier N: Conference report on public health and clinical guidelines for anthrax (conference summary). Emerg Infect Dis (serial on the Internet). 2008 Apr, cited 24 January 2011. Available from http://www.cdc.gov/EID/content/14/4/07-0969.htm.
35.
Bryskier A: Bacillus anthracis and antibacterial agents. Clin Microbiol Infect 2002;8:467-478.
36.
Vietri NJ, Purcell BK, Tobery SA, Rasmussen SL, Leffel EK, Twenhafel NA, Ivins BE, Kellogg MD, Webster WM, Wright ME, Friedlander AM: A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics. J Infect Dis 2009;199:336-341.
37.
Allerberger F, Lechner A, Wechsler-Fördös A, Gareis R: Optimization of antibiotic use in hospitals-antimicrobial stewardship and the EU project ABS international. Chemotherapy 2008;54:260-267.
38.
Kurt H, Karabay O, Birengel S, Memikoglu O, Yılmaz Bozkurt G, Yalçı A: Effects of legal antibiotic restrictions on consumption of broad-spectrum β-lactam antibiotics, glycopeptides and amphotericin B. Chemotherapy 2010;56:359-363.
39.
Lincoln RE, Klein F, Walker JS, Haines BW, Jones WI, Mahlandt BG, Friedman RH: Successful treatment of rhesus monkeys for septicemic anthrax. Antimicrob Agents Chemother 1964;10:759-763.
40.
Doust JY, Sarkarzadeh A, Kavoossi K: Corticosteroid in treatment of malignant edema of chest wall and neck (anthrax). Dis Chest 1968;53:773-774.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.